Heart failure quadruple therapy's market transformation — the convergence of four pharmacological drug classes — ACE inhibitors/ARBs/ARNi (sacubitril-valsartan), beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors — into an evidence-based quadruple combination therapy standard for heart failure with reduced ejection fraction (HFrEF) that simultaneously...